Navigation Links
Denosumab delayed time to first skeletal-related side effect
Date:12/10/2010

SAN ANTONIO For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient," said Alison T. Stopeck, M.D., associate professor of medicine and director of the Clinical Breast Cancer Program at the Arizona Cancer Center, University of Arizona, Tucson.

The Food and Drug Administration approved denosumab, sold by Amgen as XGEVA starting Nov. 18, 2010, for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

Previous results from this Phase III trial indicated that denosumab was superior to zoledronic acid in delaying the time to first on-study, skeletal-related side effects, such as fracture, radiation to bone, surgery to bone or spinal cord compression in patients with breast cancer and bone metastases. These results detail an additional four months of blinded treatment.

Stopeck and colleagues randomized 2,046 patients with advanced breast cancer to receive either 120 mg of subcutaneous denosumab or 4 mg of intravenous zoledronic acid every four weeks. Both of these drugs inhibit osteoclasts, or the cells that break down bone, therefore, all patients took calcium and vitamin D daily.

Denosumab was better at delaying the time to first on-study, skeletal-related event by 18 percent and the time to first and subsequent event by 22 percent. The median time to first on-study, skeletal-related event was five months longer for the denosumab group compared to the zoledronic acid group.

Overall survival and disease progression was similar for both groups. Rates of side effects were 96.2 percent for those taking denosumab and 97.4 percent for those taking zoledronic acid. Jaw osteonecrosis occurred in 2.5 percent of patients taking denosumab and 1.8 percent of those taking zoledronic acid.

Stopeck thinks these results will be practice changing. "We now have an alternative to zoledronic acid that is more convenient, less toxic and more effective for patients with bone metastases," she said.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Pain Relief Often Delayed for Cancer Patients
2. Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds
3. $18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section
4. New study confirms positive effects of delayed school start times
5. For HIV-positive patients, delayed treatment a costly decision
6. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
7. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
8. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
9. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
10. MSU launches first anti-counterfeiting research program
11. AMA Joins First Lady in Fight Against Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... Gaithersburg, MD (PRWEB) , ... February 08, 2016 ... ... (AHCC) is excited to share this important news! AHCC and the Home Health ... (AHA) Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to ...
(Date:2/8/2016)... ... ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal growth ... on February 10th. During this time, people can achieve better health, greater wealth, ... from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/7/2016)... Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... correct pelvic organ prolapse with the latest techniques and the most minimally invasive ... for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among ... plans to construct a medical cannabis cultivation facility and dispensary on tribal ... of New York as a provider for patients in the ... York as a provider for patients in the state,s Medical ... 29% (34) to approve the project and pursue designation from the ...
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Knee Reconstruction Devices Market by Product ... Implants), and Geography (U.S., Canada, Eu-5, Japan, Bric, ... 2020" report to their offering. ... of the "Knee Reconstruction Devices Market by ...
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
Breaking Medicine Technology: